Skip to search formSkip to main contentSkip to account menu

BGG492

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

selurampanel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Investigational small molecules in phase II clinical trials for the treatment of epilepsy
ABSTRACT Introduction: Epilepsy is a neurological disorder that significantly impacts the quality of life of affected persons… 
2018
2018
An update: emerging drugs for tinnitus
ABSTRACT Introduction: During the last decade, a number of candidate drugs for the treatment of tinnitus have emerged with the… 
2017
2017
BGG492 as an adjunctive treatment in patients with partial‐onset seizures: A 12‐week, randomized, double‐blind, placebo‐controlled, phase II dose‐titration study with an open‐label extension
To evaluate dose–response relationship of BGG492 as add‐on therapy to 1–3 antiepileptic drugs in patients with partial‐onset… 
2015
2015
Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship
Examine the efficacy of a competitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA)/kainate glutamate receptor… 
2014
2014
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks
Background Glutamate is implicated in migraine pathophysiology; amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)